[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Browse MMP2

Summary
SymbolMMP2
Namematrix metallopeptidase 2
Aliases TBE-1; CLG4; CLG4A; matrix metalloproteinase 2 (gelatinase A, 72kDa gelatinase, 72kDa type IV collagenase); ......
Chromosomal Location16q12.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Isoform 1: Secreted, extracellular space, extracellular matrix. Membrane. Nucleus. Note=Colocalizes with integrin alphaV/beta3 at the membrane surface in angiogenic blood vessels and melanomas. Found in mitochondria, along microfibrils, and in nuclei of cardiomyocytes.; SUBCELLULAR LOCATION: Isoform 2: Cytoplasm. Mitochondrion.
Domain PF00040 Fibronectin type II domain
PF00045 Hemopexin
PF00413 Matrixin
PF01471 Putative peptidoglycan binding domain
Function

Ubiquitinous metalloproteinase that is involved in diverse functions such as remodeling of the vasculature, angiogenesis, tissue repair, tumor invasion, inflammation, and atherosclerotic plaque rupture. As well as degrading extracellular matrix proteins, can also act on several nonmatrix proteins such as big endothelial 1 and beta-type CGRP promoting vasoconstriction. Also cleaves KISS at a Gly-|-Leu bond. Appears to have a role in myocardial cell death pathways. Contributes to myocardial oxidative stress by regulating the activity of GSK3beta. Cleaves GSK3beta in vitro. Involved in the formation of the fibrovascular tissues in association with MMP14.; FUNCTION: PEX, the C-terminal non-catalytic fragment of MMP2, posseses anti-angiogenic and anti-tumor properties and inhibits cell migration and cell adhesion to FGF2 and vitronectin. Ligand for integrinv/beta3 on the surface of blood vessels.; FUNCTION: Isoform 2: Mediates the proteolysis of CHUK/IKKA and initiates a primary innate immune response by inducing mitochondrial-nuclear stress signaling with activation of the pro-inflammatory NF-kappaB, NFAT and IRF transcriptional pathways.

> Gene Ontology
 
Biological Process GO:0001101 response to acid chemical
GO:0001501 skeletal system development
GO:0001503 ossification
GO:0001525 angiogenesis
GO:0001666 response to hypoxia
GO:0001704 formation of primary germ layer
GO:0001706 endoderm formation
GO:0001955 blood vessel maturation
GO:0001957 intramembranous ossification
GO:0007369 gastrulation
GO:0007492 endoderm development
GO:0007565 female pregnancy
GO:0007566 embryo implantation
GO:0010171 body morphogenesis
GO:0021700 developmental maturation
GO:0022617 extracellular matrix disassembly
GO:0030198 extracellular matrix organization
GO:0030574 collagen catabolic process
GO:0031349 positive regulation of defense response
GO:0032963 collagen metabolic process
GO:0033002 muscle cell proliferation
GO:0035987 endodermal cell differentiation
GO:0036072 direct ossification
GO:0036293 response to decreased oxygen levels
GO:0043062 extracellular structure organization
GO:0043200 response to amino acid
GO:0044236 multicellular organism metabolic process
GO:0044243 multicellular organism catabolic process
GO:0044259 multicellular organismal macromolecule metabolic process
GO:0044706 multi-multicellular organism process
GO:0045088 regulation of innate immune response
GO:0045089 positive regulation of innate immune response
GO:0048013 ephrin receptor signaling pathway
GO:0048514 blood vessel morphogenesis
GO:0048659 smooth muscle cell proliferation
GO:0048660 regulation of smooth muscle cell proliferation
GO:0048661 positive regulation of smooth muscle cell proliferation
GO:0048705 skeletal system morphogenesis
GO:0060323 head morphogenesis
GO:0060324 face development
GO:0060325 face morphogenesis
GO:0060343 trabecula formation
GO:0060346 bone trabecula formation
GO:0061383 trabecula morphogenesis
GO:0061430 bone trabecula morphogenesis
GO:0070482 response to oxygen levels
GO:0071229 cellular response to acid chemical
GO:0071230 cellular response to amino acid stimulus
GO:0071417 cellular response to organonitrogen compound
GO:0071695 anatomical structure maturation
GO:1904705 regulation of vascular smooth muscle cell proliferation
GO:1904707 positive regulation of vascular smooth muscle cell proliferation
GO:1990874 vascular smooth muscle cell proliferation
Molecular Function GO:0004175 endopeptidase activity
GO:0004222 metalloendopeptidase activity
GO:0004252 serine-type endopeptidase activity
GO:0008236 serine-type peptidase activity
GO:0008237 metallopeptidase activity
GO:0017171 serine hydrolase activity
Cellular Component GO:0005578 proteinaceous extracellular matrix
GO:0030016 myofibril
GO:0030017 sarcomere
GO:0043292 contractile fiber
GO:0044449 contractile fiber part
> KEGG and Reactome Pathway
 
KEGG hsa04670 Leukocyte transendothelial migration
hsa04912 GnRH signaling pathway
hsa04915 Estrogen signaling pathway
Reactome R-HSA-1592389: Activation of Matrix Metalloproteinases
R-HSA-422475: Axon guidance
R-HSA-1442490: Collagen degradation
R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-1474228: Degradation of the extracellular matrix
R-HSA-1266738: Developmental Biology
R-HSA-2682334: EPH-Ephrin signaling
R-HSA-3928665: EPH-ephrin mediated repulsion of cells
R-HSA-1474244: Extracellular matrix organization
R-HSA-168256: Immune System
R-HSA-6785807: Interleukin-4 and 13 signaling
R-HSA-5683057: MAPK family signaling cascades
R-HSA-5687128: MAPK6/MAPK4 signaling
R-HSA-392499: Metabolism of proteins
R-HSA-381426: Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
R-HSA-162582: Signal Transduction
R-HSA-449147: Signaling by Interleukins
Summary
SymbolMMP2
Namematrix metallopeptidase 2
Aliases TBE-1; CLG4; CLG4A; matrix metalloproteinase 2 (gelatinase A, 72kDa gelatinase, 72kDa type IV collagenase); ......
Chromosomal Location16q12.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between MMP2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between MMP2 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
29683683melanomaPromote immunity (T cell function); increase the efficacy of immunotherapyTo achieve this, an amphiphilic peptide, consisting of a functional 3-diethylaminopropyl isothiocyanate (DEAP) molecule, a peptide substrate of matrix metalloproteinase-2 (MMP-2), and DPPA-1, was synthesized and coassembled with NLG919.
16891318GlioblastomaPromote immunityYet again, MP inhibition by the broad spectrum inhibitors GM 6001 or MMP inhibitor III selectively enhanced the expression of MICA and ULBP2 on the surface of LNT- 229 cells but not of other NKG2DL (Fig. 4A). For MICA, this effect was significantly more prominent on control than on TGF-b1/2 siRNA cells. Thus, escape from NKG2D-mediated immune surveillance of malignant gliomas in vivo may be promoted by the inhibition of MICA and ULBP2 expression via an autocrine TGF-beta loop and by MP-dependent shedding from the cell surface.
Summary
SymbolMMP2
Namematrix metallopeptidase 2
Aliases TBE-1; CLG4; CLG4A; matrix metalloproteinase 2 (gelatinase A, 72kDa gelatinase, 72kDa type IV collagenase); ......
Chromosomal Location16q12.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of MMP2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolMMP2
Namematrix metallopeptidase 2
Aliases TBE-1; CLG4; CLG4A; matrix metalloproteinase 2 (gelatinase A, 72kDa gelatinase, 72kDa type IV collagenase); ......
Chromosomal Location16q12.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of MMP2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-1.7860.00256
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-1.9240.503
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-1.6750.401
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.5580.333
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.8220.779
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.2260.951
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.6670.326
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-1.1630.576
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.3570.89
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.930.659
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 282.7270.347
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.3110.151
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of MMP2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277311.11.49.70.0589
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275911.11.79.40.0895
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)2117011.8-11.80.193
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)86016.7-16.70.429
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 38277.907.90.26
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.109.10.519
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 111307.7-7.71
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 51208.3-8.31
Summary
SymbolMMP2
Namematrix metallopeptidase 2
Aliases TBE-1; CLG4; CLG4A; matrix metalloproteinase 2 (gelatinase A, 72kDa gelatinase, 72kDa type IV collagenase); ......
Chromosomal Location16q12.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of MMP2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolMMP2
Namematrix metallopeptidase 2
Aliases TBE-1; CLG4; CLG4A; matrix metalloproteinase 2 (gelatinase A, 72kDa gelatinase, 72kDa type IV collagenase); ......
Chromosomal Location16q12.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of MMP2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by MMP2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolMMP2
Namematrix metallopeptidase 2
Aliases TBE-1; CLG4; CLG4A; matrix metalloproteinase 2 (gelatinase A, 72kDa gelatinase, 72kDa type IV collagenase); ......
Chromosomal Location16q12.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of MMP2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolMMP2
Namematrix metallopeptidase 2
Aliases TBE-1; CLG4; CLG4A; matrix metalloproteinase 2 (gelatinase A, 72kDa gelatinase, 72kDa type IV collagenase); ......
Chromosomal Location16q12.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of MMP2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolMMP2
Namematrix metallopeptidase 2
Aliases TBE-1; CLG4; CLG4A; matrix metalloproteinase 2 (gelatinase A, 72kDa gelatinase, 72kDa type IV collagenase); ......
Chromosomal Location16q12.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between MMP2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolMMP2
Namematrix metallopeptidase 2
Aliases TBE-1; CLG4; CLG4A; matrix metalloproteinase 2 (gelatinase A, 72kDa gelatinase, 72kDa type IV collagenase); ......
Chromosomal Location16q12.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting MMP2 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting MMP2.
ID Name Drug Type Targets #Targets
DB00786MarimastatSmall MoleculeMMP1, MMP10, MMP11, MMP12, MMP13, MMP14, MMP15, MMP16, MMP17, MMP1 ......23
DB01197CaptoprilSmall MoleculeACE, BDKRB1, LTA4H, MMP2, MMP95
DB01630SC-74020Small MoleculeMMP21
DB04866HalofuginoneSmall MoleculeCOL1A1, MMP22
DB05387AE-941Small MoleculeMMP12, MMP2, MMP93